PDCD1 and colon adenocarcinoma: In support of this expectation are recent studies showing that the anti-helmintic drug niclosamide and the CDK inhibitor dinaciclib enhanced the efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer and colon adenocarcinoma, respectively [47,48].